Efficacy and safety of atazanavir-ritonavir plus abacavir-lamivudine or tenofovir-emtricitabine in patients with hyperlipidaemia switched from a stable protease inhibitor-based regimen including one thymidine analogue

AIDS Patient Care and STDs

Volumn 23, Issue 9, 2009, Pages 691-697

  Calza, Leonardo ^a   Manfredi, Roberto ^a   Colangeli, Vincenzo ^a   Pocaterra, Daria ^a   Rosseti, Nirmala ^a   Pavoni, Michele ^a   Chiodo, Francesco ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; ATAZANAVIR PLUS RITONAVIR; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; LOPINAVIR PLUS RITONAVIR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR PLUS SAQUINAVIR; STAVUDINE; THYMIDINE DERIVATIVE; ZIDOVUDINE;

ABDOMINAL PAIN; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANXIETY; ARTICLE; BILIRUBIN BLOOD LEVEL; CD4 LYMPHOCYTE COUNT; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; FATIGUE; FEMALE; FLATULENCE; FOLLOW UP; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLIPIDEMIA; HYPOPHOSPHATEMIA; JAUNDICE; MACULOPAPULAR RASH; MAJOR CLINICAL STUDY; MALE; NAUSEA; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SLEEP DISORDER;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ANTIVIRAL AGENTS; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; HYPERLIPIDEMIAS; MALE; MIDDLE AGED; PILOT PROJECTS; PROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; THYMIDINE; TREATMENT OUTCOME;

EID: 70349213594     PISSN: 10872914     EISSN: None     Source Type: Journal    
DOI: 10.1089/apc.2009.0039     Document Type: Article

References (35)

1. Galli M, Ridolfo AL, Adorni F, et al. Body habitus changes and metabolic alterations in protease inhibitor-native HIV-1infected patients treated with two nucleoside reverse transcriptase inhibitors. J Acquir Immune Defic Syndr 2002;29: 21-31.
2. Jones R, Sawleshwarkar S, Michailidis C, et al. Impact of antiretroviral choice on hypercholesterolaemia events: The role of the nucleoside reverse transcriptase inhibitor backbone. HIV Med 2005;6:396-402.
3. Behrens G, Dejam A, Schmidt H, et al. Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. AIDS 1999; 13:63-70.
4. Graham NM. Metabolic disorders among HIV-infected patients treated with protease inhibitors: A review. J Acquir Immune Defic Syndr 2000;25(Suppl 1):S4-S11.
5. Calza L, Manfredi R, Chiodo F. Hyperlipidaemia in patients with HIV-1 infection receiving highly active antiretroviral therapy: Epidemiology, pathogenesis, clinical course and management. Int J Antimicrob Agents 2003;22:89-99.
6. Distler O, Cooper DA, Deckelbaum RJ, Sturley SL. Hyperlipidemia and inhibitors of HIV protease. Curr Opin Clin Nutr Metab Care 2001;4:99-103.
7. Mulligan K, Grunfeld C, Tai VW, et al. Hyperlipidemia and insulin resistance are induced by protease inhibitors indipendent of changes in body composition in patients with HIV infection. J Acquir Immune Defic Syndr 2000;23:35-43.
8. Paparizos VA, Kyriakys KP, Botsis C, Papastamopoulos V, Hadjivassiliou M, Stavrianeas NG. Protease inhibitor therapy-associated lipodystrophy, hypertriglyceridemia and diabetes mellitus. AIDS 2000;14:903-905.
9. d'Arminio Monforte A, Sabin CA, Phillips AN, et al. Cardioand cerebrovascular events in HIV-infected persons. AIDS 2004;18:1811-1817.
10. Mary-Krause M, Cotte L, Simon A, Partisani M, Costagliola D; the Clinical Epidemiology Group from the French Hospital Database. Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS 2003;17:2479-2486.
11. The Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007;356:1723-1735.
12. Bucher HC, Young J, Battegay M. Protease inhibitor-sparing simplified maintenance therapy: A need for perspective. J Antimicrob Chemother 2004;54:303-305.
13. Drechsler H, Powderly WG. Switching effective antiretroviral therapy: A review. Clin Infect Dis 2002;35:1219-1230.
14. Johnson M, Grinsztejn B, Rodriguez C, et al. 96-week comparison of once-daily atazanavir-ritonavir and twice-daily lopinavir-ritonavir in patients with multiple virologic failures. AIDS 2006;20:711-718.
15. Gatell J, Salmon-Ceron D, Lazzarin A, et al. efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched froma a stable, boosted or unboosted protease inhibitor treatment regimen: The SWAN Study (AI424-097) 48-week results. Clin Infect Dis 2007;44:1484-1492.
16. Domingo P, Labarga P, Palacios R, et al. Improvement of dyslipidaemia in patients switching from stavudine to tenofovir: Preliminary results. AIDS 2004;18:1475-1477.
17. Moyle GJ, Baldwin C, Langroudi B, Mandalia S, Gazzard BG. A 48-week, randomized, open-label comparison of three abacavir-based substitution approaches in the management of dyslipidaemia and peripheral lipoatrophy. J Acquir Immune Defic Syndr 2003;33:22-28.
18. D:A:D: Study Group. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: A multi-cohort collaboration. Lancet 2008;371:1417-1426.
19. Orrick JJ, Steinhart CR. Atazanavir. Ann Pharmacother 2004;38:1664-1674.
20. Cahn PE, Gatell JM, Squires K, et al. Atazanavir-A once-daily HIV protease inhibitor that does not cause dyslipidemia in newly treated patients: Results from two randomized clinical trials. J Int Assoc Physicians AIDS Care (Chic Ill) 2004;3: 92-98.
21. Mobius U, Lubach-Ruitman M, Castro-Frenzel B, et al. Switching to atazanavir improves metabolic disorders in antiretroviral-experienced patients with severe hyperlipidemia. J Acquir Immune Defic Syndr 2005;39:174-180.
22. Soriano V, Garcia-Gasco P, Vispo E, et al. efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: Final results of the SLOAT trial. J Antimicrob Chemother 2008;61:200-205.
23. Nguyen ST, Eaton SA, Bain AM, et al. Lipid-lowering efficacy and safety after switching to atazanavir-ritonavirbased highly active antiretroviral therapy in patients with human immunodeficiency virus. Pharmacotherapy 2008;28: 323-330.
24. Moyle GJ, Sabin CA, Cartledge J, et al. A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy. AIDS 2006;20:2043-2050.
25. Gallant JE, Staszewski S, Pozniak AL, et al. efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-native patients: A 3-year randomized trial. JAMA 2004;292:191-201.
26. Gallant JE, DeJesus E, Arribas JR, et al. Tenofovir DF, emtricitabine, and efavirenz vs zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 2006;354:251-260.
27. Ananworanich J, Nuesch R, Coté HC, et al. Changes in metabolic toxicity after switching from stavudine=didanosine to tenofovir=lamivudine: A Staccato trial substudy. J Antimicrob Chemother 2008;61:1340-1343.
28. Arribas JR, Pozniak AL, Gallant JE, et al. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine=lamivudine and efavirenz in treatmentnafive patients. J Acquir Immune Defic Syndr 2008;47:74-78.
29. Madruga JR, Cassetti I, Suleiman JM, et al. The safety and efficacy of switching stavudine to tenofovir df in combination with lamivudine and efavirenz in HIV-1-infected patients: Three-year follow-up after switching therapy. HIV Clin Trials 2007;8:381-390. (Pubitemid 350305212)
30. Llibre JM, Domingo P, Palacios R, et al. Sustained improvement of dyslipidaemia in HAART-treated patients replacing stavudine with tenofovir. AIDS 2006;20:1407-1414.
31. DeJesus E, Ruane P, McDonald C, et al. Impact of switching virologically suppressed HIV-1-infected patients from twice-daily fixed-dose zidovudine-lamivudine to once-daily fixed-dose tenofovir disoproxil fumarate-emtricitabine. HIV Clin Trials 2008;9:103-114.
32. Podzamczer D, Ferrer E, Sanchez P, et al. Less lipoatrophy and better lipid profile with abacavir as compared to stavudine: 96-week results of a randomized study. J Acquir Immune Defic Syndr 2007;44:139-147.
33. Keiser PH, Sension MG, DeJesus E, et al. Substituting abacavir for hyperlipidaemia-associated protease inhibitors in HAART regimens improves fasting lipid profiles, maintains virologic suppression, and simplifies treatment. BMC Infect Dis 2005;5:2.
34. Strategies for Management of Anti-Retroviral Therapy= INSIGHT; DAD Study Groups. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. AIDS 2008;22:F17-F24.
35. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. November 3, 2008; pp. 1-139. www.aidsinfo.nih.gov=ContentFiles=AdultandAdolescentGL.pdf (Last accessed June 28, 2009).